According to Pharmarack, unlike the previous two years where October sales for Oral Rehydration Solutions (ORS) is lesser ...
Pedersen COPENHAGEN (Reuters) -Shares in Novo Nordisk rose on Monday after the Wegovy maker lost out to Pfizer in a $10 ...
NEW YORK/LONDON (Reuters) -U.S. drugmaker Pfizer has clinched a $10 billion deal for obesity drug developer Metsera, capping ...
“No need for a reunion show: This seasons Real Housewives of Biopharma comes to a close with Pfizer’s winning bid for Metsera ...
New research finds no link between Tylenol use during pregnancy and autism, despite Trump’s claims
Despite President Trump’s claims, scientists don’t have enough evidence to say acetaminophen use during pregnancy is linked ...
Here are some of the stocks making notable moves in Monday's premarket action: TreeHouse Foods shares are surging 19% after the food and beverage company agreed to be taken private by Industrial F&B ...
Metsera shares fell significantly as the firm accepted a $10 billion offer from Pfizer, ending its bidding war with Novo Nordisk. Despite the dip, Metsera shares have surged since Pfizer's initial ...
Novo Nordisk stock rose 2.6% after withdrawing from a $10 billion bidding war for Metsera that investors viewed as too ...
2h
Pfizer won its fight to buy an obesity-drug maker. It took an extra $1.7 billion and a phone call.
Pfizer is buying its way back into the obesity-drug game after fighting off a rival bid from Novo Nordisk to buy Metsera, ...
Metsera shares fell sharply in premarket trading Monday after the weight-loss drug startup struck a revised deal to be acquired by Pfizer, prompting Danish drugmaker Novo Nordisk to drop out of a ...
Pfizer Is Buying Weight-Loss Drugmaker Metsera. Why Novo Nordisk Is the Real Winner.
Just as U.S. households were fretting about the effect on travel and the wider economy of the longest-ever government ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback